QOP
EBS icon

Quinn Opportunity Partners’s Emergent Biosolutions EBS Stock Holding History

Quinn Opportunity Partners’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-57,742
Closed -$2.89M – 218
2021
Q3 		$2.89M Sell
57,742
-7,000
-11% -$424K 0.19% 99
2021
Q2 		$4.08M Buy
+64,742
New +$4.16M 0.25% 82

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Quinn Opportunity Partners's EBS Position: Q4 2021 in Review

Quinn Opportunity Partners sold out of Emergent Biosolutions (EBS) in Q4 2021, closing a stake of 57,742 shares — an estimated $2.89M sold.

Quinn Opportunity Partners first reported a position in EBS in Q2 2021 and held it in 2 quarters. The position peaked at $4.08M in Q2 2021. 254 funds tracked by Wall St. Rank hold EBS as of Q4 2021.

  • Quinn Opportunity Partners reported no remaining Emergent Biosolutions position as of Q4 2021 after selling out during the quarter.
  • Quinn Opportunity Partners sold 57,742 Emergent Biosolutions shares in Q4 2021, an estimated $2.89M.
  • Quinn Opportunity Partners first reported a position in Emergent Biosolutions in Q2 2021 and held it in 2 quarters.
  • Quinn Opportunity Partners's Emergent Biosolutions position peaked at $4.08M in Q2 2021.
  • 254 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2021.

Based on Quinn Opportunity Partners's 13F filing for Q4 2021, filed 14 Feb 2022.